AI boosts genome editing
Researchers at the University of Zurich have developed a new tool that uses artificial intelligence…
The gene-editing tool CRISPR-Cas9 has taken over the life sciences world since its development in 2012. CRISPR has changed the way biology research is done, simplifying and speeding up the study of diseases and the discovery of drugs, as well as having a huge impact on crop and food development. Among all its possible applications, the fact that CRISPR can be used to tweak the human genome has made it especially promising for previously difficult-to-treat diseases.
But how does CRISPR work? What kind of therapies are being developed? How is the genome-editing market evolving? And how are stakeholders navigating the complex intellectual property around this technology? Find out the answers to these questions and more on this page.
The Genome Editing Toolbox: ZFNS, TALENS, and CRISPR in Biomedicine
This report covers the industry’s most common genome-editing tools, like CRISPR-Cas9, provides exclusive insights by experts, looks at the market, and addresses future applications and challenges of genome-editing tools.
Go to ReportResearchers at the University of Zurich have developed a new tool that uses artificial intelligence…
Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics have announced that the European Medicines Agency (EMA) has…
Aldevron, which develops and manufactures plasmid DNA, RNA and proteins for the biotech industry, has…
Arix Bioscience, a global venture capital company focused on investing in breakthrough biotechnology companies, announced…
Scientists at the Helmholtz Institute Würzburg in Germany, and Benson Hill, Inc. (Missouri) and Utah…
By: Alina Su, CEO and founder of NovaXS Biotech Corp The next generation of biotech…
Actinium Pharmaceuticals, Inc. has entered into a research collaboration with Columbia University to study Actimab-A,…
For several years, the CRISPR/Cas9 gene scissors have been causing a sensation in science and…
Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system…
PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing…
Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S.…
Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of…